Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
diabetes mellitus4971 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A03884 | 33833450 | Nat Rev Cardiol | Global epidemiology of dyslipidaemias. | 2021 | Details |
| A03886 | 33833347 | Sci Rep | Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis. | 2021 | Details |
| A03887 | 33832846 | Z Med Phys | Towards detection of inflammation in adipose tissue: Microscopic field simulations to estimate water signal properties. | 2021 | Details |
| A03892 | 33831474 | Adv Drug Deliv Rev | Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. | 2021 | Details |
| A03893 | 33830112 | Mymensingh Med J | Study on Alanine Aminotransferase in Patients of Type 2 Diabetes Mellitus. | 2021 | Details |
| A03910 | 33822497 | Int J Med Mushrooms | Bioactive Components and Possible Activities of Medicinal Mushrooms in Alleviating the Pathogenesis of Nonalcoholic Fatty Liver Disease (Review). | 2021 | Details |
| A03911 | 33822317 | Hepatol Int | Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait. | 2021 | Details |
| A03914 | 33820884 | Gut Liver | Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. | 2021 | Details |
| A03924 | 33815743 | Ther Adv Endocrinol Metab | Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. | 2021 | Details |
| A03931 | 33813683 | Obes Surg | Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass. | 2021 | Details |
| A03941 | 33811369 | JPEN J Parenter Enteral Nutr | Body composition measured by bioelectrical impedance analysis is a viable alternative to magnetic resonance imaging in children with nonalcoholic fatty liver disease. | 2021 | Details |
| A03958 | 33808007 | Int J Mol Sci | Momordica cochinchinensis Aril Ameliorates Diet-Induced Metabolic Dysfunction and Non-Alcoholic Fatty Liver by Modulating Gut Microbiota. | 2021 | Details |
| A03988 | 33800585 | Int J Environ Res Public Health | Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity. | 2021 | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | 2021 | Details |
| A03997 | 33795579 | Eur J Gastroenterol Hepatol | Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus. | 2021 | Details |
| A04010 | 33790119 | Yakugaku Zasshi | [VNUT Is a Therapeutic Target for Type 2 Diabetes and NASH]. | 2021 | Details |
| A04018 | 33788095 | Dig Dis Sci | Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. | 2021 | Details |
| A04031 | 33783745 | Adv Exp Med Biol | Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). | 2021 | Details |
| A04037 | 33780425 | MEDICC Rev | Non-Alcoholic Fatty Liver Disease in Cuba. | 2021 | Details |
| A04058 | 33773656 | Food Res Int | Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. | 2021 | Details |
| A04061 | 33772908 | Biofactors | The role of biofactors in the prevention and treatment of age-related diseases. | 2021 | Details |
| A04069 | 33771638 | J Ethnopharmacol | Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs. | 2021 | Details |
| A04089 | 33763391 | Can J Gastroenterol Hepatol | Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. | 2021 | Details |
| A04090 | 33763324 | Cureus | Glycogen Hepatopathy: A Reversible yet Relapsing Cause of Hepatitis in Type 1 Diabetics. | 2021 | Details |
| A04092 | 33762835 | Diabetes Metab Syndr Obes | Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. | 2021 | Details |
| A04116 | 33751877 | Clin Mol Hepatol | From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? | 2021 | Details |
| A04125 | 33748726 | JHEP Rep | NAFLD and MAFLD as emerging causes of HCC: A populational study. | 2021 | Details |
| A04126 | 33746906 | Front Endocrinol (Lausanne) | Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. | 2021 | Details |
| A04128 | 33746742 | Front Pharmacol | Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway. | 2021 | Details |
| A04129 | 33746450 | J Clin Exp Hepatol | Long-term Management of the Adult Liver Transplantation Recipients. | 2020 | Details |
| A04130 | 33746449 | J Clin Exp Hepatol | What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? | 2020 | Details |
| A04143 | 33743291 | Clin Nutr | U-shaped association between the triglyceride-glucose index and the risk of incident diabetes in people with normal glycemic level: A population-base longitudinal cohort study. | 2021 | Details |
| A04146 | 33742318 | Curr Diab Rep | The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. | 2021 | Details |
| A04152 | 33739984 | PLoS One | Association between sarcopenia level and metabolic syndrome. | 2021 | Details |
| A04157 | 33736456 | Antioxid Redox Signal | Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk. | 2021 | Details |
| A04161 | 33733078 | JHEP Rep | European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease? | 2021 | Details |
| A04163 | 33732030 | Clin Pharmacol | Clinical Impact of Liraglutide as a Treatment of Obesity. | 2021 | Details |
| A04180 | 33725855 | Medicine (Baltimore) | Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. | 2021 | Details |
| A04182 | 33724511 | Hepatology | Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A04185 | 33723650 | Acta Diabetol | The long-term metabolic and neurocognitive risks in offspring of women with type 1 diabetes mellitus. | 2021 | Details |
| A04204 | 33716004 | Metabolism | Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. | 2021 | Details |
| A04212 | 33711631 | Clin Res Hepatol Gastroenterol | The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study. | 2021 | Details |
| A04227 | 33707081 | Best Pract Res Clin Endocrinol Metab | Gut microbiome and bile acids in obesity-related diseases. | 2021 | Details |
| A04228 | 33706959 | Vitam Horm | Ghrelin and adipokines: An overview of their physiological role, antimicrobial activity and impact on cardiovascular conditions. | 2021 | Details |
| A04232 | 33705650 | Diabetes Metab J | Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. | 2021 | Details |
| A04235 | 33694195 | J Gastroenterol Hepatol | Oxidized low-density lipoprotein activates extracellular signal-regulated kinase signaling to downregulate sortilin expression in liver sinusoidal endothelial cells. | 2021 | Details |
| A04254 | 33688229 | Diabetes Metab Syndr Obes | Risk Factors Screening for Gestational Diabetes Mellitus Heterogeneity in Chinese Pregnant Women: A Case-Control Study. | 2021 | Details |
| A04271 | 33681089 | Can J Gastroenterol Hepatol | NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. | 2021 | Details |
| A04286 | 33677935 | Endocrinol Metab (Seoul) | Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. | 2021 | Details |
| A04288 | 33676874 | Surg Obes Relat Dis | The metabolic and liver-related outcomes of bariatric surgery in adult patients with insulin-treated type 2 diabetes and nonalcoholic fatty liver disease at high risk of liver fibrosis. | 2020 | Details |
| A04291 | 33675475 | Int Urol Nephrol | Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography. | 2021 | Details |
| A04303 | 33671880 | Biomedicines | Immunomodulatory Role of Urolithin A on Metabolic Diseases. | 2021 | Details |
| A04327 | 33664710 | Front Endocrinol (Lausanne) | Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis. | 2021 | Details |
| A04336 | 33659890 | JHEP Rep | Case-finding strategies in non-alcoholic fatty liver disease. | 2020 | Details |
| A04337 | 33659827 | Vavilovskii Zhurnal Genet Selektsii | Apoptosis in the liver of male db/db mice during the development of obesity and type 2 diabetes. | 2020 | Details |
| A04354 | 33650781 | Physiol Rep | Serum fetuin-A and Ser312 phosphorylated fetuin-A responses and markers of insulin sensitivity after a single bout of moderate intensity exercise. | 2021 | Details |
| A04356 | 33648923 | Eur Cytokine Netw | Absence of increased liver-related inflammatory markers in type 1 diabetes with metabolic syndrome: a nested case-control study from Brazil. | 2020 | Details |
| A04359 | 33648515 | Cardiovasc Diabetol | Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. | 2021 | Details |
| A04362 | 33647823 | Int Immunopharmacol | The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. | 2021 | Details |
| A04365 | 33647502 | Ann Hepatol | The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. | 2021 | Details |
| A04371 | 33643221 | Front Endocrinol (Lausanne) | Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. | 2021 | Details |
| A04374 | 33642826 | World J Gastroenterol | Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. | 2021 | Details |
| A04377 | 33642355 | Saudi J Gastroenterol | The effect of hepatic steatosis on COVID-19 severity: Chest computed tomography findings. | 2021 | Details |
| A04384 | 33640265 | J Diabetes Complications | Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. | 2021 | Details |
| A04393 | 33636655 | Clin Res Hepatol Gastroenterol | Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort. | 2021 | Details |
| A04407 | 33630451 | Ann Surg | Long-term Metabolic Morbidity and Steatohepatosis Following Standard Pancreatic Resections and Parenchyma-sparing, Local Extirpations for Benign Tumor: A Systematic Review and Meta-analysis. | 2022 | Details |
| A04418 | 33626072 | PLoS One | Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. | 2021 | Details |
| A04423 | 33622213 | Am J Chin Med | Intestinal Flora: A Pivotal Role in Investigation of Traditional Chinese Medicine. | 2021 | Details |
| A04431 | 33618780 | Br J Nutr | Dietary and metabolic risk of neuropsychiatric disorders: insights from animal models. | 2021 | Details |
| A04439 | 33616043 | J Diabetes Complications | Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. | 2020 | Details |
| A04461 | 33606661 | Eur J Endocrinol | Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. | 2021 | Details |
| A04472 | 33603757 | Front Immunol | Extracellular Vesicles as Inflammatory Drivers in NAFLD. | 2021 | Details |
| A04475 | 33602617 | J Diabetes Complications | Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. | 2021 | Details |
| A04478 | 33601426 | Exp Clin Endocrinol Diabetes | Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. | 2021 | Details |
| A04481 | 33601024 | Endocr Pract | Association Between Non-Alcoholic Fatty Liver Disease and Diabetes-Related Microvascular Complications: A Retrospective Cross-Sectional Study of Hospitalized Patients. | 2021 | Details |
| A04488 | 33598647 | JHEP Rep | Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. | 2020 | Details |
| A04490 | 33598084 | Pan Afr Med J | Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes. | 2020 | Details |
| A04492 | 33597157 | Gut | Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. | 2021 | Details |
| A04495 | 33596938 | J Transl Med | Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. | 2021 | Details |
| A04506 | 33594581 | Diabetes Ther | Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. | 2021 | Details |
| A04509 | 33593749 | BMJ Open Diabetes Res Care | Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. | 2021 | Details |
| A04512 | 33592910 | Medicine (Baltimore) | Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis. | 2021 | Details |
| A04522 | 33588049 | Free Radic Biol Med | Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. | 2021 | Details |
| A04524 | 33587330 | Phytother Res | Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. | 2021 | Details |
| A04534 | 33585009 | Gastroenterol Hepatol Bed Bench | Showing NAFLD, as a key connector disease between Alzheimer's disease and diabetes via analysis of systems biology. | 2020 | Details |
| A04542 | 33584134 | J Med Biochem | The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. | 2021 | Details |
| A04547 | 33583033 | Eur J Clin Invest | Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. | 2021 | Details |
| A04562 | 33579423 | Adv Cancer Res | NAFLD-related HCC. | 2021 | Details |
| A04563 | 33579000 | Int J Mol Sci | IL-6 Reduces Mitochondrial Replication, and IL-6 Receptors Reduce Chronic Inflammation in NAFLD and Type 2 Diabetes. | 2021 | Details |
| A04566 | 33578624 | Medicine (Baltimore) | Gender-specific association between non-alcoholic fatty liver disease and type 2 diabetes mellitus among a middle-aged and elderly Chinese population: An observational study. | 2021 | Details |
| A04568 | 33578292 | Biochem Biophys Res Commun | Mesenchymal stem cell-conditioned medium improved mitochondrial function and alleviated inflammation and apoptosis in non-alcoholic fatty liver disease by regulating SIRT1. | 2021 | Details |
| A04576 | 33574823 | Front Immunol | Self-Nucleic Acid Sensing: A Novel Crucial Pathway Involved in Obesity-Mediated Metaflammation and Metabolic Syndrome. | 2021 | Details |
| A04580 | 33573891 | J Diabetes Complications | Importance of non-invasive liver fibrosis scores for mortality and complications development in individuals with type 2 diabetes. | 2021 | Details |
| A04583 | 33573385 | Rev Esp Enferm Dig | Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hepática metabólica (EHmet). | 2021 | Details |
| A04585 | 33572797 | Cancers (Basel) | The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. | 2021 | Details |
| A04594 | 33569991 | Arch Physiol Biochem | The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: a review. | 2021 | Details |
| A04599 | 33568418 | BMJ Open Gastroenterol | Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. | 2021 | Details |
| A04600 | 33567710 | Int J Environ Res Public Health | Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. | 2021 | Details |
| A04612 | 33564251 | Diabetes Metab Syndr Obes | A Non-Invasive Prediction Model for Non-Alcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Based on the Population of Northern Urumqi, China. | 2021 | Details |
| A04614 | 33562458 | Pharmaceuticals (Basel) | The Current and Potential Therapeutic Use of Metformin-The Good Old Drug. | 2021 | Details |